Vantage Consulting Group Inc Spectrum Pharmaceuticals Inc Transaction History

Vantage Consulting Group Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$0.63 - $1.59 $18,384 - $46,397	-29,181 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$1.27 - $2.42 $11,976 - $22,820	9,430 Added 47.74%	29,181 $37,000
Q3 2021 Nov 10, 2021	BUY	$2.15 - $3.82 $20,074 - $35,667	9,337 Added 89.66%	19,751 $43,000
Q2 2021 Aug 11, 2021	SELL	$2.89 - $4.45 $3,676 - $5,660	-1,272 Reduced 10.88%	10,414 $39,000
Q1 2021 May 14, 2021	BUY	$2.9 - $4.09 $20,358 - $28,711	7,020 Added 150.45%	11,686 $38,000
Q4 2020 Feb 12, 2021	BUY	$3.38 - $5.14 $15,771 - $23,983	4,666 New	4,666 $16,000

115K

Ticker SPPI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 188,164,000
Description
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor ...

Get notified when there are updates to the investment portfolio of Vantage Consulting Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vantage Consulting Group Inc with notifications on news.